CD274 and non-small cell lung carcinoma: This cohort included 240 patients with NSCLC treated with anti‐PD‐L1 alone or in combination with anti‐cytotoxic T‐cell lymphocyte‐4 (anti‐CTLA‐4) therapeutic scheme.